BioXcel Therapeutics Inc (OQ:BTAI)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 555 Long Wharf Dr
NEW HAVEN CT 06511-6107
Tel: 1-312-5232372
Website: www.bioxceltherapeutics.com
IR: See website
<
Key People
Peter Mueller
Independent Chairman of the Board
Vimal Mehta
President, Chief Executive Officer, Secretary, Director
Richard I. Steinhart
Chief Financial Officer
Frank D. Yocca
Chief Scientific Officer
Vincent J. O'Neill
Chief Medical Officer
 
Business Overview
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.
Financial Overview
For the fiscal year ended 31 December 2019, BioXcel Therapeutics Inc revenues was not reported. Net loss increased 71% to $33M. Higher net loss reflects Research and development increase of 77% to $25.8M (expense), General and administrative increase of 44% to $7.8M (expense), Dividend and interest income, net decrease of 9% to $633K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.32 to -$2.02.
Employees: 24 as of Dec 31, 2019
Reporting Currency: U.S. Dollars
Enterprise value: $364.56M as of Dec 31, 2019
Annual revenue (TTM): $0.00M as of Dec 31, 2019
EBITDA (TTM): -$33.45M as of Dec 31, 2019
Net annual income (TTM): -$32.97M as of Dec 31, 2019
Free cash flow (TTM): -$28.15M as of Dec 31, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 20,182,382 as of Mar 9, 2020
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization